COMPARE · Data as of August 28, 2026
DOC vs NHI
Verdict: Side-by-side breakdown using the Bull Rankings model. DOC scored 69.0, NHI scored 74.0 — NHI leads.
Compare another set
Different reporting periods. DOC's fundamentals are as of June 2026, but NHI's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
DOC
Healthpeak Properties, Inc.
66.9Fin
$21.12 · $15.0B
fundamentals as of
Strength gap
5.9
NHI leads
NHI
National Health Investors, Inc.
72.8Fin
$72.03 · $3.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthNHI+12.1%
- Strongest balance sheetNHI0.98
Side by side · every name on one set of axes
Fundamentals, head-to-head
DOC
NHI
5.7%A-
Yield
5.2%A-
+4.5%C+
Rev
+12.1%B+
1.09B
D/E
0.98B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
The companies
DOCHealthpeak Properties, Inc.
Why now
REIT - Healthcare Facilities · market cap $15.0b. 8% off the 52-week high of $22.95. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $22.92 (implying +9% upside).
Moat
Moat signals from the quantitative card are modest — profitability and capital efficiency are middle-of-pack. The thesis here depends on softer factors (switching costs, brand, distribution, regulatory protection) not captured by the quality-growth screen.
Risk
Dividend payout 349% of earnings on a 5.7% yield — distribution coverage is thin; one earnings stumble could force a dividend cut. ROE 3% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
NHINational Health Investors, Inc.
Why now
REIT - Healthcare Facilities · market cap $3.5b. Down 21% from 52-week high of $91.38 — deep drawdown territory. Revenue growing +12%, comfortably above the S&P median. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $82.13 (implying +14% upside).
Moat
Net margin 38% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere.
Risk
Dividend payout 106% of earnings on a 5.2% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.